This year’s Nobel Prize in Medicine honors the discovery of regulatory T cells (Tregs)
and the transcription factor FoxP3 – fundamental mechanisms that keep the immune
system in balance. These are the same biological processes that form the basis of
TIRmed Pharma’s research.
The discovery of Tregs reshaped immunology by revealing how the body prevents excessive
immune responses and autoimmune reactions. It also opened new possibilities for therapies
that aim not only to suppress inflammation, but to restore immune balance – an approach
central to TIRmed’s work.
TIRmed Pharma is developing TIR-C, a topical treatment for atopic dermatitis (eczema)
designed to modulate the immune system through the induction of regulatory T cells (iTregs).
The drug contains the active substance TIR-01, an immunomodulatory oligonucleotide that
helps re-establish immune tolerance in the skin. By promoting the body’s natural ability to
regulate inflammation, rather than merely blocking it, TIR-C aims to offer patients more
durable and well-tolerated relief.
“The Nobel Prize underscores the importance of immune regulation in health and disease,”
says Leo Holmgren, CEO of TIRmed Pharma. “Our work builds directly on these
mechanisms, with the goal of translating them into effective and lasting treatments for
patients suffering from chronic inflammatory conditions.”
With its roots in cutting-edge immunology, TIRmed continues to advance a new generation of
treatments that address the underlying misdirected autoimmune reactions in skin diseases.